MA27996A1 - Nouvelle composition comprenant la rosiglitazone et un autre agent antidiabetique - Google Patents
Nouvelle composition comprenant la rosiglitazone et un autre agent antidiabetiqueInfo
- Publication number
- MA27996A1 MA27996A1 MA28817A MA28817A MA27996A1 MA 27996 A1 MA27996 A1 MA 27996A1 MA 28817 A MA28817 A MA 28817A MA 28817 A MA28817 A MA 28817A MA 27996 A1 MA27996 A1 MA 27996A1
- Authority
- MA
- Morocco
- Prior art keywords
- antidiabetic agent
- rosiglitazone
- another antidiabetic
- novel composition
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Une forme posologique orale comprenant un noyau érodable, noyau qui comprend le Composé A ou un de ses sels ou produits de solvatation pharmaceutiquement acceptables et un autre agent antidiabétique, le noyau comprenant un enrobage avec un ou plusieurs orifices, caractérisé en ce que l'enrobage est érodable dans des conditions de pH prédéterminées ; un procédé pour la préparation d'une telle forme posologique et l'utilisation d'une telle forme posologique en médecine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0318824.0A GB0318824D0 (en) | 2003-08-11 | 2003-08-11 | Novel composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27996A1 true MA27996A1 (fr) | 2006-07-03 |
Family
ID=27840010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28817A MA27996A1 (fr) | 2003-08-11 | 2006-02-17 | Nouvelle composition comprenant la rosiglitazone et un autre agent antidiabetique |
Country Status (37)
Country | Link |
---|---|
US (1) | US20080206336A1 (fr) |
EP (1) | EP1663191B1 (fr) |
JP (1) | JP4714147B2 (fr) |
KR (1) | KR20060071396A (fr) |
CN (2) | CN1835741B (fr) |
AP (1) | AP2006003489A0 (fr) |
AR (1) | AR045230A1 (fr) |
AT (1) | ATE455542T1 (fr) |
AU (1) | AU2004262933B2 (fr) |
BR (1) | BRPI0413419A (fr) |
CA (1) | CA2534480A1 (fr) |
CY (1) | CY1109923T1 (fr) |
DE (1) | DE602004025257D1 (fr) |
DK (1) | DK1663191T3 (fr) |
EA (2) | EA200800966A1 (fr) |
EC (1) | ECSP066338A (fr) |
ES (1) | ES2339554T3 (fr) |
GB (1) | GB0318824D0 (fr) |
HK (1) | HK1092051A1 (fr) |
HR (1) | HRP20100160T1 (fr) |
IL (1) | IL173177A0 (fr) |
IS (1) | IS2745B (fr) |
MA (1) | MA27996A1 (fr) |
MX (1) | MXPA06001629A (fr) |
MY (1) | MY151053A (fr) |
NO (1) | NO20061161L (fr) |
NZ (1) | NZ544632A (fr) |
OA (1) | OA13233A (fr) |
PE (1) | PE20050357A1 (fr) |
PL (1) | PL1663191T3 (fr) |
PT (1) | PT1663191E (fr) |
SG (1) | SG165178A1 (fr) |
SI (1) | SI1663191T1 (fr) |
TW (1) | TW200517146A (fr) |
UA (1) | UA82537C2 (fr) |
UY (1) | UY28461A1 (fr) |
WO (1) | WO2005013956A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR030920A1 (es) * | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
WO2005051325A2 (fr) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Base libre de carvedilol, ses sels, formes anhydres ou solvats, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et methodes de traitement ou d'administration |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100120906A1 (en) * | 2008-07-18 | 2010-05-13 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
WO2011161521A1 (fr) * | 2010-06-21 | 2011-12-29 | Lupin Limited | Compositions comprenant de la metformine et de la rosiglitazone |
RU2016125229A (ru) * | 2010-07-09 | 2018-12-04 | БиЭйчВи ФАРМА, ИНК. | Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина |
CN105663130B (zh) * | 2011-04-15 | 2019-08-09 | 江苏豪森药业集团有限公司 | 一种具有第一和第二活性药物的制剂 |
CN118001246A (zh) * | 2024-01-31 | 2024-05-10 | 四川鲁徽制药有限责任公司 | 一种达格列净、吡格列酮复方缓释片及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
US20020006939A1 (en) * | 1997-10-13 | 2002-01-17 | Smithkline Beecham P.L.C. | Use of thiazolidinediones for the treatment of hyperglycaemia |
EP1067910B1 (fr) * | 1998-04-03 | 2004-05-26 | Egalet A/S | Composition a liberation controllee |
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
ATE315629T1 (de) * | 1998-11-10 | 2006-02-15 | Procter & Gamble | Bleichmittelzusammensetzungen |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
WO2000028989A1 (fr) * | 1998-11-12 | 2000-05-25 | Smithkline Beecham P.L.C. | Composition pharmaceutique a liberation modifiee d'un agent de sensibilisation a l'insuline, et d'un autre agent antidiabetique |
JP2003514011A (ja) * | 1999-11-16 | 2003-04-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物 |
AU2001257456B2 (en) * | 2000-05-01 | 2006-02-09 | Aeropharm Technology, Inc. | A core formulation |
GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
GB0120835D0 (en) * | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
PE20030800A1 (es) * | 2002-02-12 | 2003-10-31 | Glaxo Group Ltd | Forma de dosificacion oral de liberacion controlada |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
-
2003
- 2003-08-11 GB GBGB0318824.0A patent/GB0318824D0/en not_active Ceased
-
2004
- 2004-08-09 BR BRPI0413419-2A patent/BRPI0413419A/pt not_active IP Right Cessation
- 2004-08-09 OA OA1200600045A patent/OA13233A/en unknown
- 2004-08-09 PL PL04741403T patent/PL1663191T3/pl unknown
- 2004-08-09 AT AT04741403T patent/ATE455542T1/de active
- 2004-08-09 UY UY28461A patent/UY28461A1/es not_active Application Discontinuation
- 2004-08-09 DK DK04741403.2T patent/DK1663191T3/da active
- 2004-08-09 JP JP2006522974A patent/JP4714147B2/ja not_active Expired - Fee Related
- 2004-08-09 SI SI200431376T patent/SI1663191T1/sl unknown
- 2004-08-09 US US10/567,803 patent/US20080206336A1/en not_active Abandoned
- 2004-08-09 MY MYPI20043234 patent/MY151053A/en unknown
- 2004-08-09 EP EP04741403A patent/EP1663191B1/fr not_active Expired - Lifetime
- 2004-08-09 CA CA002534480A patent/CA2534480A1/fr not_active Abandoned
- 2004-08-09 SG SG200901679-1A patent/SG165178A1/en unknown
- 2004-08-09 AR ARP040102846A patent/AR045230A1/es not_active Application Discontinuation
- 2004-08-09 NZ NZ544632A patent/NZ544632A/en not_active IP Right Cessation
- 2004-08-09 AP AP2006003489A patent/AP2006003489A0/xx unknown
- 2004-08-09 DE DE602004025257T patent/DE602004025257D1/de not_active Expired - Lifetime
- 2004-08-09 EA EA200800966A patent/EA200800966A1/ru unknown
- 2004-08-09 CN CN2004800232304A patent/CN1835741B/zh not_active Expired - Fee Related
- 2004-08-09 CN CN2011103143770A patent/CN102397551A/zh active Pending
- 2004-08-09 AU AU2004262933A patent/AU2004262933B2/en not_active Ceased
- 2004-08-09 PT PT04741403T patent/PT1663191E/pt unknown
- 2004-08-09 EA EA200600400A patent/EA011550B1/ru not_active IP Right Cessation
- 2004-08-09 ES ES04741403T patent/ES2339554T3/es not_active Expired - Lifetime
- 2004-08-09 MX MXPA06001629A patent/MXPA06001629A/es active IP Right Grant
- 2004-08-09 WO PCT/EP2004/008970 patent/WO2005013956A1/fr active Application Filing
- 2004-08-09 KR KR1020067002884A patent/KR20060071396A/ko not_active Application Discontinuation
- 2004-08-09 PE PE2004000771A patent/PE20050357A1/es not_active Application Discontinuation
- 2004-08-09 TW TW093123804A patent/TW200517146A/zh unknown
- 2004-09-08 UA UAA200601353A patent/UA82537C2/uk unknown
-
2006
- 2006-01-16 IL IL173177A patent/IL173177A0/en unknown
- 2006-01-31 EC EC2006006338A patent/ECSP066338A/es unknown
- 2006-02-17 MA MA28817A patent/MA27996A1/fr unknown
- 2006-03-02 IS IS8337A patent/IS2745B/is unknown
- 2006-03-10 NO NO20061161A patent/NO20061161L/no not_active Application Discontinuation
- 2006-11-15 HK HK06112571.6A patent/HK1092051A1/xx not_active IP Right Cessation
-
2010
- 2010-03-18 HR HR20100160T patent/HRP20100160T1/hr unknown
- 2010-03-22 CY CY20101100261T patent/CY1109923T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27996A1 (fr) | Nouvelle composition comprenant la rosiglitazone et un autre agent antidiabetique | |
MA27779A1 (fr) | FORME CRISTALLINE D'AGONISTE DE RECEPTEUR β2 ADRENERGIQUE | |
TNSN05176A1 (fr) | Derives de diazepino-indole servant d'inhibiteurs de kinases | |
MA29550B1 (fr) | Derives de n- (pyridine-2-yl) - sulfonamide | |
NO980669D0 (no) | Orale raskt-opplöselige blandinger for dopaminagonister | |
IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
NO20085077L (no) | Nye forbindelser | |
TNSN00065A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant. | |
HUP0301194A2 (hu) | Dipeptidil-peptidáz IV. inhibitorokból és más antidiabetikus szerekből álló kombinációs készítmények és alkalmazásuk diabetes mellitus kezelésére | |
MA29451B1 (fr) | Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme | |
NO971470L (no) | Nye pyrimidon-derivater med fungicid aktivitet | |
EP2412707A3 (fr) | Derives d'acide 3-[2-(3-amino-2-oxo-2H-pyridin-1-yl) acetylamino]-4-oxo-pentanoique et leur utilisation comme inhibiteurs de caspase | |
GEP20043383B (en) | Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds | |
MA27980A1 (fr) | Nouvelle composition | |
AP1780A (en) | Use of cox-2 inhibitors for preventing immunodeficiency. | |
GEP20074045B (en) | (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease | |
GEP20053626B (en) | Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof | |
MA27605A1 (fr) | Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel | |
MA27021A1 (fr) | Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant | |
IL128851A (en) | Pharmaceutical composition for lowering the uric acid level in the human body | |
HUP0004780A2 (hu) | Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében | |
AP1736A (en) | Oral dosage form for controlled drug release. | |
CA2005976A1 (fr) | Agents contenant des derives imidazole pour la lutte systematique contre les ectoparasites chez les animaux hotes et nouveaux derives d'imidazoline | |
EP0976404A3 (fr) | Compositions pharmaceutiques pour la prévention et la therapie de troubles cognitifes chez les mammifères |